L Wijaya1, Y Y Chua, L Cui, K Chan, B H Tan. 1. Department of Infectious Diseases, Singapore General Hospital, Outram Road, Singapore 169608. limin.wijaya@sgh.com.sg
Abstract
INTRODUCTION: The 2009 (H1N1) influenza A pandemic started in April 2009 and has since spread globally. We have noticed that critically ill patients with confirmed pandemic 2009 (H1N1) influenza A require mechanical ventilation. This paper describes the use of intravenous zanamivir in this group of patients. METHODS: Patients who had severe pneumonia with 2009 (H1N1) influenza A and required intravenous zanamivir were referred to the Infectious Diseases Department of our institution. Clinical data was collected from these patients. Clinical samples were sent to the National Public Health Laboratory for sequencing. RESULTS: A total of five patients used intravenous zanamivir from April 8 to May 8, 2010. Only one death was reported. There were no side effects attributable to the use of intravenous zanamivir. H275 mutation, which confers resistance to oseltamivir, was seen in a subpopulation of the virus in one case. CONCLUSION: Physicians can consider using intravenous zanamivir for the treatment of critically ill patients with 2009 (H1N1) influenza A infection.
INTRODUCTION: The 2009 (H1N1) influenza A pandemic started in April 2009 and has since spread globally. We have noticed that critically illpatients with confirmed pandemic 2009 (H1N1) influenza A require mechanical ventilation. This paper describes the use of intravenous zanamivir in this group of patients. METHODS:Patients who had severe pneumonia with 2009 (H1N1) influenza A and required intravenous zanamivir were referred to the Infectious Diseases Department of our institution. Clinical data was collected from these patients. Clinical samples were sent to the National Public Health Laboratory for sequencing. RESULTS: A total of five patients used intravenous zanamivir from April 8 to May 8, 2010. Only one death was reported. There were no side effects attributable to the use of intravenous zanamivir. H275 mutation, which confers resistance to oseltamivir, was seen in a subpopulation of the virus in one case. CONCLUSION: Physicians can consider using intravenous zanamivir for the treatment of critically illpatients with 2009 (H1N1) influenzaA infection.
Authors: Magdalena Świerczyńska; Dagmara M Mirowska-Guzel; Edyta Pindelska Journal: Int J Environ Res Public Health Date: 2022-03-04 Impact factor: 3.390